Answers are grounded in this paper and cite their sources.
Phase I trial evaluates DOC1021 for glioblastoma treatment, suggesting potential benefits of combining therapies.
To report ongoing results of an expanded access protocol evaluating DOC1021 in adult patients with new or recurrent glioblastoma.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: